Psychiatric And Sexual Dysfunction Warnings Strengthened For Finasteride And Dutasteride

    The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that additional information regarding psychiatric and sexual side effects will be included in the product information for medications containing finasteride and dutasteride. This decision follows a review of evidence for both drugs, as detailed in a drug safety update published on 11 May 2026. The MHRA recommends further measures to address these concerns.
    Discuss this study in the Community →